Antiemetics: ASCO guideline update
Purpose: To update the guideline to include new anticancer agents, antiemetics, and antiemetic regimens and to provide recommendations on the use of dexamethasone as a prophylactic antiemetic in patients receiving checkpoint inhibitors (CPIs). Methods: ASCO convened an Expert Panel and updated the s...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
July 13, 2020
|
| In: |
Journal of clinical oncology
Year: 2020, Volume: 38, Issue: 24, Pages: 2782-2797 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.20.01296 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1200/JCO.20.01296 Verlag, lizenzpflichtig, Volltext: https://ascopubs.org/doi/10.1200/JCO.20.01296 
|
| Author Notes: | Paul J. Hesketh, Mark G. Kris, Ethan Basch, Kari Bohlke, Sally Y. Barbour, Rebecca Anne Clark-Snow, Michael A. Danso, Kristopher Dennis, L. Lee Dupuis, Stacie B. Dusetzina, Cathy Eng, Petra C. Feyer, Karin Jordan, Kimberly Noonan, Dee Sparacio, and Gary H. Lyman |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1737379449 | ||
| 003 | DE-627 | ||
| 005 | 20220819005435.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201029s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.20.01296 |2 doi | |
| 035 | |a (DE-627)1737379449 | ||
| 035 | |a (DE-599)KXP1737379449 | ||
| 035 | |a (OCoLC)1341375323 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hesketh, Paul |e VerfasserIn |0 (DE-588)1160971706 |0 (DE-627)102436366X |0 (DE-576)506294471 |4 aut | |
| 245 | 1 | 0 | |a Antiemetics |b ASCO guideline update |c Paul J. Hesketh, Mark G. Kris, Ethan Basch, Kari Bohlke, Sally Y. Barbour, Rebecca Anne Clark-Snow, Michael A. Danso, Kristopher Dennis, L. Lee Dupuis, Stacie B. Dusetzina, Cathy Eng, Petra C. Feyer, Karin Jordan, Kimberly Noonan, Dee Sparacio, and Gary H. Lyman |
| 264 | 1 | |c July 13, 2020 | |
| 300 | |a 16 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 29.10.2020 | ||
| 520 | |a Purpose: To update the guideline to include new anticancer agents, antiemetics, and antiemetic regimens and to provide recommendations on the use of dexamethasone as a prophylactic antiemetic in patients receiving checkpoint inhibitors (CPIs). Methods: ASCO convened an Expert Panel and updated the systematic review to include randomized controlled trials (RCTs) and meta-analyses of RCTs published between June 1, 2016, and January 24, 2020. To address the dexamethasone and CPI question, we conducted a systematic review of RCTs that evaluated the addition of a CPI to chemotherapy. Results: The systematic reviews included 3 publications from the updated search and 10 publications on CPIs. Two phase III trials in adult patients with non-small-cell lung cancers evaluating a platinum-based doublet with or without the programmed death 1 (PD-1) inhibitor pembrolizumab recommended that all patients receive dexamethasone as a component of the prophylactic antiemetic regimen. In both studies, superior outcomes were noted in the PD-1 inhibitor-containing arms. Other important findings address olanzapine in adults and fosaprepitant in pediatric patients. Recommendations: Recommendations for adults are unchanged with the exception of the option of adding olanzapine in the setting of hematopoietic stem cell transplantation. Dosing information now includes the option of a 5-mg dose of olanzapine in adults and intravenous formulations of aprepitant and netupitant-palonosetron. The option of fosaprepitant is added to pediatric recommendations. There is no clinical evidence to warrant omission of dexamethasone from guideline-compliant prophylactic antiemetic regimens when CPIs are administered to adults in combination with chemotherapy. CPIs administered alone or in combination with another CPI do not require the routine use of a prophylactic antiemetic. Additional information is available at www.asco.org/supportive-care-guidelines. | ||
| 700 | 1 | |a Kris, Mark G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Basch, Ethan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bohlke, Kari |e VerfasserIn |4 aut | |
| 700 | 1 | |a Barbour, Sally Y. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Clark-Snow, Rebecca Anne |e VerfasserIn |4 aut | |
| 700 | 1 | |a Danso, Michael A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dennis, Kristopher |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dupuis, L. Lee |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dusetzina, Stacie B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Eng, Cathy |e VerfasserIn |4 aut | |
| 700 | 1 | |a Feyer, Petra C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jordan, Karin |d 1974- |e VerfasserIn |0 (DE-588)123243327 |0 (DE-627)706224078 |0 (DE-576)293619174 |4 aut | |
| 700 | 1 | |a Noonan, Kimberly |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sparacio, Dee |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lyman, Gary H. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 38(2020), 24, Seite 2782-2797 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Antiemetics ASCO guideline update |
| 773 | 1 | 8 | |g volume:38 |g year:2020 |g number:24 |g pages:2782-2797 |g extent:16 |a Antiemetics ASCO guideline update |
| 856 | 4 | 0 | |u https://doi.org/10.1200/JCO.20.01296 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/10.1200/JCO.20.01296 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20201029 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 123243327 |a Jordan, Karin |m 123243327:Jordan, Karin |d 910000 |d 910100 |e 910000PJ123243327 |e 910100PJ123243327 |k 0/910000/ |k 1/910000/910100/ |p 13 | ||
| 999 | |a KXP-PPN1737379449 |e 3789161578 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Paul J. Hesketh, Mark G. Kris, Ethan Basch, Kari Bohlke, Sally Y. Barbour, Rebecca Anne Clark-Snow, Michael A. Danso, Kristopher Dennis, L. Lee Dupuis, Stacie B. Dusetzina, Cathy Eng, Petra C. Feyer, Karin Jordan, Kimberly Noonan, Dee Sparacio, and Gary H. Lyman"]},"recId":"1737379449","note":["Gesehen am 29.10.2020"],"language":["eng"],"id":{"doi":["10.1200/JCO.20.01296"],"eki":["1737379449"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"July 13, 2020"}],"title":[{"title_sort":"Antiemetics","title":"Antiemetics","subtitle":"ASCO guideline update"}],"person":[{"role":"aut","given":"Paul","display":"Hesketh, Paul","family":"Hesketh"},{"role":"aut","family":"Kris","display":"Kris, Mark G.","given":"Mark G."},{"given":"Ethan","family":"Basch","display":"Basch, Ethan","role":"aut"},{"given":"Kari","family":"Bohlke","display":"Bohlke, Kari","role":"aut"},{"role":"aut","given":"Sally Y.","family":"Barbour","display":"Barbour, Sally Y."},{"given":"Rebecca Anne","display":"Clark-Snow, Rebecca Anne","family":"Clark-Snow","role":"aut"},{"role":"aut","display":"Danso, Michael A.","family":"Danso","given":"Michael A."},{"display":"Dennis, Kristopher","family":"Dennis","given":"Kristopher","role":"aut"},{"family":"Dupuis","display":"Dupuis, L. Lee","given":"L. Lee","role":"aut"},{"role":"aut","given":"Stacie B.","display":"Dusetzina, Stacie B.","family":"Dusetzina"},{"role":"aut","given":"Cathy","display":"Eng, Cathy","family":"Eng"},{"given":"Petra C.","display":"Feyer, Petra C.","family":"Feyer","role":"aut"},{"display":"Jordan, Karin","family":"Jordan","given":"Karin","role":"aut"},{"given":"Kimberly","display":"Noonan, Kimberly","family":"Noonan","role":"aut"},{"role":"aut","given":"Dee","family":"Sparacio","display":"Sparacio, Dee"},{"given":"Gary H.","display":"Lyman, Gary H.","family":"Lyman","role":"aut"}],"physDesc":[{"extent":"16 S."}],"relHost":[{"disp":"Antiemetics ASCO guideline updateJournal of clinical oncology","note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"pubHistory":["1.1983 -"],"recId":"313116962","origin":[{"dateIssuedKey":"1983","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","dateIssuedDisp":"1983-"}],"part":{"pages":"2782-2797","text":"38(2020), 24, Seite 2782-2797","volume":"38","issue":"24","year":"2020","extent":"16"},"title":[{"title_sort":"Journal of clinical oncology","title":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal"}],"physDesc":[{"extent":"Online-Ressource"}],"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"id":{"issn":["1527-7755"],"zdb":["2005181-5"],"eki":["313116962"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"corporate":[{"display":"American Society of Clinical Oncology","role":"isb"}]}]} | ||
| SRT | |a HESKETHPAUANTIEMETIC1320 | ||